3:40 PM
 | 
Dec 14, 2018
 |  BioCentury  |  Emerging Company Profile

ExCellThera’s safer allogeneic transplants

How ExCellThera is increasing the safety of allogeneic stem cell transplants

ExCellThera Inc. is expanding cord blood into allogeneic stem cell transplants for cancer that have lower treatment-related mortality rates and GvHD incidence than competing technologies.

Hematopoietic stem cell transplants (HSCTs) of unexpanded cord blood have two key drawbacks, according to CFO and Chief Legal Officer David Millette. First, only about 5% of cord blood samples contain enough stem cells to treat an adult, restricting their use. Second, despite having a lower rate of chronic graft-versus-host disease (GvHD) than standard of care (SOC) bone marrow or peripheral blood transplants, unexpanded cord blood transplants have a treatment-related mortality (TRM) rate of about 30%, roughly twice that of SOC.

ExCellThera’s lead technology, ECT-001, addresses both problems by expanding the number of stem cells in cord blood and reducing TRM rates. ECT-001 is a combination of UM171 -- a small molecule with an undisclosed...

Read the full 678 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >